de Faria AP, Modolo R, Chichareon P, et al. - In an all-comers percutaneous coronary intervention (PCI) population, researchers undertook this analysis of GLOBAL LEADERS (n = 15,936) in order to assess the link of pulse pressure (PP) and various antiplatelet regimes with clinical and safety results. Among individuals who had PCI and categorized into two groups based on median PP (60 mmHg), comparisons were performed between experimental therapy of 23-month ticagrelor following one-month dual anti-platelet therapy (DAPT), vs standard DAPT for 12 months followed by aspirin monotherapy. Findings revealed high rates of net adverse clinical events at 2-years in participants with high PP levels, following contemporary PCI. Lower risk of bleeding events was observed in relation to ticagrelor monotherapy vs standard DAPT in those with low PP.